Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Urine test predicts Alzheimer’s disease

14.06.2002


A simple clinical test could make it easier to track and treat Alzheimer’s



A urine sample taken at the doctor’s office can be the step in determining your chances of developing Alzheimer’s disease (AD), according to researchers at the University of Pennsylvania School of Medicine. They have determined that a urine test can reliably detect free radical damage associated with people with Mild Cognitive Impairment (MCI) – a recognized precursor to AD. The test detects isoprostanes, fatty acids that are formed as the result of free radical damage in the brain – damage that correlates with clinical diagnosis of AD.

"This is the first noninvasive test that can predict a clinical diagnosis of Alzheimer’s disease," said Domenico Praticò, MD, assistant professor in Penn’s Department of Pharmacology. "Since there is no cure for Alzheimer’s disease, physicians could slow the course of the disease if it is caught early enough."


Within four years of initial diagnosis, up to 50% of people with MCI develop Alzheimer’s disease. As AD progresses, it attacks the brain and causes severe damage in the areas important for memory, judgement, and language. This destruction leads to other clinical complications and, eventually, death.

In the study, published in the June edition of Archives of Neurology, Praticò and his colleagues measured isoprostane in blood and urine samples obtained from 50 patients with a clinical diagnosis of AD, 33 patients with MCI, and 40 healthy volunteers. Two weeks later, a CSF sample and a second urine sample were taken from 28 of the AD patients, 17 of the MCI patients, and 18 of the control subjects. The researchers found significantly higher levels of isoprostane in CSF, blood, and urine of MCI and AD subjects than in the volunteers. Remarkably, the samples taken from the MCI subjects and the volunteers differed only in respect to their isoprostane levels.

"We found that patients with MCI have increased brain oxidative damage before the onset of AD – damage that can be detected in the form of isoprostanes in urine, as this study shows," said Praticò. "In fact, five MCI subjects, all with high isoprostane levels, converted to AD during follow-up."

Patients that are diagnosed with Mild Cognitive Impairment typically present their physicians with persistent memory loss that is not normal for someone of their age and education. Although their memory is impaired, MCI patients are capable of living largely independent lives. At this stage, it is difficult to determine whether a person with MCI will eventually have Alzheimer’s or whether they will progress to a form of unrelated dementia.

A urine sample taken in the doctor’s office may be a first point of decision in gauging the risk of developing AD. Further tests could then determine the severity of a patient’s condition and course of treatment. For example, studies have shown that the transition from MCI to AD occurs fastest in people who have a gene called apoE4 and whose brain’s hippocampus region is shown to be smaller as measured in an MRI scan.

"One hypothesis is that, in AD, healthy brain tissue is damaged by the local formation of large amounts of free radicals," said Praticò. "Isoprostanes are the byproducts of fats in the human body that were warped by free radical attack. They then accumulate in CSF, blood, and urine as the body works to get rid of them."

While at the moment this test is not yet clinically available, the team is working on the development of a version of it that could be broadly and easily performed.

Unlike a spinal tap, a urine test is simple to do and provides a painless and noninvasive way of assessing the situation. "The advantages are clear: with an easier test, doctors can diagnose the disease sooner and respond better to the patient’s needs," said Praticò.


This research was supported by grants from the National Institutes of Health and the American Heart Association. Trial participants were selected at the Memory Disorders Clinic of Penn’s Alzheimer’s Disease Center.


Greg Lester | EurekAlert

More articles from Health and Medicine:

nachricht Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

nachricht FAU researchers demonstrate that an oxygen sensor in the body reduces inflammation
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Stiffness matters

22.02.2018 | Life Sciences

Magnetic field traces gas and dust swirling around supermassive black hole

22.02.2018 | Physics and Astronomy

First evidence of surprising ocean warming around Galápagos corals

22.02.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>